Summary
The CYVADIC combination has been the preferred treatment for soft tissue sarcomas for the last 10 years. Other combinations of therapy are necessary because the remission rate achieved with CYVADIC is only thirty per cent. Alternative therapies for these tumours are combinations includingcis-platinum, ifosfamide, epipodophyllin and high-dose methotrexate. Our therapeutic results with combinations ofcis-platinum and ifosfamide are comparable to CYVADIC. However, side-effects such as nausea, vomiting and fatigue due tocis-platinum in the palliative treatment of these tumours are intolerable for many patients. A combination of adriamycin and ifosfamide, which exhibites a higher remission rate of 44% and lower toxicity than CYVADIC, is giving encouraging results.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- CR:
-
complete remission
- CYVADIC:
-
cyclophosphamid,vincristin,adriamycin
- DTIC :
-
dacarbazin
- DDP:
-
cis-platinum
- IFO:
-
ifosfamide
- NC:
-
no change
- PD:
-
progressive disease
- PR:
-
partial remission
- SD:
-
stable disease
References
Bierbaum W, Bremer K, Ferusian N, Higi M, Niederle N, Scheulen ME, Schmidt CG, Seeber S (1981) Chemotherapeutische Behandlung bei fortgeschrittenen Sarkomen. DMW 37:1181–1185
Chang AE, Rosenberg SA (1984) Quality of life after different treatment modalities for soft tissue sarcomas. Review of NCI studies. Proc. of the Symposium “Management of Soft Tissue and Bone Sarcomas”, Utrecht, The Nederlands. 17–19 Juni 1984
Cvitkovic E, Spaulding J, Bethone V, Martin J, Withmore WF (1977) Improvement ofcis-dichlorodiamine-platinum (NSC 119875) Therapeutic index in an animal model. Cancer 39:1357
Enzinger FM (1984) Clinico-pathologico relation of soft tissue sarcomas. Review of NCI studies. Proc. of the Symposium “Management of Soft Tissue and Bone Sarcomas”, Utrecht, The Nederlands. 17–19 Juni 1984
Enzinger FM, Weiss SW (1983) Soft tissue tumours. C.V. Mosby, St. Louis Toronto London
Gottlieb JA, Baker LH, O'Bryan RM, Sinkovics JG, Hoogstraten B, Quagliana JM, Rivkin SE, Bodey GP, Rodriguez VT, Blumenschein GR, Saiki JH, Coltman C, Burgess MA, Sullivan P, Thigpen T, Bottemley R, Balcerzak S, Moon TE (1975) Adriamycin (NSC-123127) used alone and in combination for soft tissue and bone sarcomas. Cancer Chemother Rep 6:271–282
Karakousis CP, Rao U, Carlson M (1980) High-dose Methotrexate as secondary chemotherapy in metastic soft tissue sarcomas. Cancer 46:1345–1348
Van Oosterom AT, Bramvell VHC, Mouridsen HT, Somers R, Santoro A, Boesa J, Vendrik CP, Roubsse J, Dombernowsky P, Pinedo HM, Thomas D, Sylvester R (1984) Review EORTC Phase II studies in advanced soft tissue sarcomas. Proc. of the Symposium “Management of Soft Tissue and Bone Sarcomas”, Utrecht, The Nederlands. 17–19 Juni 1984
Pinedo HM, Kennis Y (1977) Chemotherapy of advanced soft tissue sarcomas in adult. Cancer Treat Rev 4:67–86
Russel O, Cohen J, Enzinger FM, Hajdu SI, Heise H, Harting RC, Meissner W, Miller WD, Schmitz RL, Suite HD (1977) A clinical and pathological staging system for soft tissue sarcomas. Cancer 44:1562–1570
Seeber S (1984) Konzepte zur Chemotherapie von Weichteilsarkomen im Erwachsenenalter. Verh Dtsch Krebs Ges 5:817–821
Stuart-Harris RC, Harper PG, Parsons CA, Kaye SB, Mooney CA, Gowing NF, Wiltshaw E (1983) High-dose alkylation therapy using Ifosfamide infusion with Mesna in the treatment of adults advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 11:69–72
Author information
Authors and Affiliations
Additional information
Dedicated to Professor Dr. Hans J. Dengler on the occasion of his 60th birthday
Rights and permissions
About this article
Cite this article
Hartlapp, J.H., Münch, H.J., Illiger, H.J. et al. Alternatives to cyvadic-combination therapy of soft tissue sarcomas. Klin Wochenschr 63, 1160–1162 (1985). https://doi.org/10.1007/BF01740591
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01740591